Advertisement



Drug Shortages

Last updated

Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.

161 medicines

  • Haloperidol Decanoate Being discontinued 2 products · updated January 9, 2026

    Psychiatry

    Product Availability Expected supply / notes
    Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-05)
    Fresenius Kabi USA, LLC
    Discontinuation of the manufacture of the drug
    Being discontinued · January 9, 2026
    Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-01)
    Fresenius Kabi USA, LLC
    Discontinuation of the manufacture of the drug
    Being discontinued · January 9, 2026

    Uses, warnings and side effects from the FDA label →

  • Imipenem and Cilastatin Being discontinued 1 product · updated January 8, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Primaxin, Injection, 500mg (NDC 0006-3516-59)
    Merck Sharp & Dohme Corp.
    To be discontinued approximately 11/30/2026
    Being discontinued · January 8, 2026

    Uses, warnings and side effects from the FDA label →

  • Diltiazem Hydrochloride Being discontinued 1 product · updated January 5, 2026

    Cardiovascular

    Product Availability Expected supply / notes
    Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-4350-03)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · January 5, 2026

    Uses, warnings and side effects from the FDA label →

  • Hydroxychloroquine Sulfate Being discontinued 1 product · updated January 5, 2026

    Anti-Infective, Other, Rheumatology

    Product Availability Expected supply / notes
    Hydroxychloroquine Sulfate, Tablet, 200 mg (NDC 0093-2401-01)
    Teva Pharmaceuticals USA, Inc.
    Discontinuation of the manufacture of the drug
    Being discontinued · January 5, 2026

    Uses, warnings and side effects from the FDA label →

  • Sodium Oxybate Being discontinued 1 product · updated December 29, 2025

    Psychiatry

    Product Availability Expected supply / notes
    Sodium Oxybate, Solution, .5 g/1 mL (NDC 69238-2391-1)
    Amneal Pharmaceuticals
    Discontinuation of the manufacture of the drug
    Being discontinued · December 29, 2025

    Uses, warnings and side effects from the FDA label →

  • Mirikizumab Being discontinued 2 products · updated December 22, 2025

    Gastroenterology, Other

    Product Availability Expected supply / notes
    Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)
    Eli Lilly and Co.
    A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.
    Being discontinued · December 22, 2025
    Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)
    Eli Lilly and Co.
    A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.
    Being discontinued · December 22, 2025

    Uses, warnings and side effects from the FDA label →

  • Carbamazepine Being discontinued 3 products · updated December 19, 2025

    Neurology

    Product Availability Expected supply / notes
    Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12)
    Takeda Pharmaceuticals USA Inc.
    Discontinuation of the manufacture of the drug
    Being discontinued · December 19, 2025
    Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12)
    Takeda Pharmaceuticals USA Inc.
    Discontinuation of the manufacture of the drug
    Being discontinued · December 19, 2025
    Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12)
    Takeda Pharmaceuticals USA Inc.
    Discontinuation of the manufacture of the drug
    Being discontinued · December 19, 2025

    Uses, warnings and side effects from the FDA label →

  • Doxercalciferol Being discontinued 3 products · updated December 10, 2025

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1)
    Sanofi-Aventis U.S. LLC
    Discontinuation of the manufacture of the drug
    Being discontinued · December 10, 2025
    Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1)
    Sanofi-Aventis U.S. LLC
    Discontinuation of the manufacture of the drug
    Being discontinued · December 10, 2025
    Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1)
    Sanofi-Aventis U.S. LLC
    Discontinuation of the manufacture of the drug
    Being discontinued · December 10, 2025

    Uses, warnings and side effects from the FDA label →

  • Spironolactone Being discontinued 2 products · updated December 10, 2025

    Cardiovascular

    Product Availability Expected supply / notes
    Aldactone, Tablet, 100 mg (NDC 0025-1031-31)
    Pfizer Inc.
    Discontinuation of the manufacture of the drug.
    Being discontinued · December 10, 2025
    Aldactone, Tablet, 25 mg (NDC 0025-1001-31)
    Pfizer Inc.
    Discontinuation of the manufacture of the drug.
    Being discontinued · December 10, 2025

    Uses, warnings and side effects from the FDA label →

  • Ampicillin Sodium Being discontinued 5 products · updated December 8, 2025

    Anti-Infective

    Product Availability Expected supply / notes
    Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95)
    Sandoz Inc.
    Discontinuation of private label only
    Being discontinued · December 8, 2025
    Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92)
    Sandoz Inc.
    Discontinuation of private label only
    Being discontinued · December 8, 2025
    Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95)
    Sandoz Inc.
    Discontinuation of private label only
    Being discontinued · December 8, 2025
    Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95)
    Sandoz Inc.
    Discontinuation of private label only
    Being discontinued · December 8, 2025
    Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92)
    Sandoz Inc.
    Discontinuation of private label only
    Being discontinued · December 8, 2025

    Uses, warnings and side effects from the FDA label →

  • Calcitriol Being discontinued 2 products · updated December 4, 2025

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Calcitriol, Capsule, .5 ug (NDC 0093-7353-01)
    Teva Pharmaceuticals USA, Inc.
    A business decision was made to discontinue manufacture of the drug
    Being discontinued · December 4, 2025
    Calcitriol, Capsule, .25 ug (NDC 0093-7352-01)
    Teva Pharmaceuticals USA, Inc.
    A business decision was made to discontinue manufacture of the drug
    Being discontinued · December 4, 2025

    Uses, warnings and side effects from the FDA label →

  • Sodium Acetate Anhydrous Being discontinued 3 products · updated December 3, 2025

    Gastroenterology, Other, Renal

    Product Availability Expected supply / notes
    Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · December 3, 2025
    Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · December 3, 2025
    Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · December 3, 2025

    Uses, warnings and side effects from the FDA label →

  • Posaconazole Being discontinued 1 product · updated December 2, 2025

    Anti-Infective

    Product Availability Expected supply / notes
    Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01)
    Merck Sharp & Dohme Corp.
    Discontinuation of the manufacture of the drug
    Being discontinued · December 2, 2025

    Uses, warnings and side effects from the FDA label →

  • Nilutamide Being discontinued 2 products · updated December 1, 2025

    Oncology

    Product Availability Expected supply / notes
    Nilandron, Tablet, 150 mg (NDC 59212-111-14)
    Advanz Pharma (US) Corp.
    Product to expire in March 2026; Discontinuation of the manufacture of the drug
    Being discontinued · December 1, 2025
    Nilandron, Tablet, 150 mg (NDC 66993-212-38)
    Advanz Pharma (US) Corp.
    Product to expire in March 2026; Discontinuation of the manufacture of the drug
    Being discontinued · December 1, 2025

    Uses, warnings and side effects from the FDA label →

  • Phenoxybenzamine Hydrochloride Being discontinued 3 products · updated December 1, 2025

    Cardiovascular

    Product Availability Expected supply / notes
    Dibenzyline, Capsule, 10 mg (NDC 59212-001-02)
    Advanz Pharma (US) Corp.
    Discontinuation of the manufacture of the drug
    Being discontinued · December 1, 2025
    Dibenzyline, Capsule, 10 mg (NDC 66993-066-02)
    Advanz Pharma (US) Corp.
    Discontinuation of the manufacture of the drug
    Being discontinued · December 1, 2025
    Dibenzyline, Capsule, 10 mg (NDC 59212-001-01)
    Advanz Pharma (US) Corp.
    Discontinuation of the manufacture of the drug
    Being discontinued · December 1, 2025

    Uses, warnings and side effects from the FDA label →

  • Verapamil Hydrochloride Being discontinued 1 product · updated November 21, 2025

    Cardiovascular

    Product Availability Expected supply / notes
    Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05)
    Pfizer Inc.
    Discontinuation of the manufacture of the drug
    Being discontinued · November 21, 2025

    Uses, warnings and side effects from the FDA label →

  • Anagrelide Hydrochloride Being discontinued 2 products · updated November 19, 2025

    Hematology

    Product Availability Expected supply / notes
    Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60)
    Teva Pharmaceuticals USA, Inc.
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 19, 2025
    Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60)
    Teva Pharmaceuticals USA, Inc.
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 19, 2025

    Uses, warnings and side effects from the FDA label →

  • Hydrochlorothiazide Being discontinued 2 products · updated November 19, 2025

    Cardiovascular

    Product Availability Expected supply / notes
    Microzide, Capsule, 12.5 mg (NDC 0591-0347-01)
    Teva Pharmaceuticals USA, Inc.
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 19, 2025
    Microzide, Capsule, 12.5 mg (NDC 0591-0347-05)
    Teva Pharmaceuticals USA, Inc.
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 19, 2025

    Uses, warnings and side effects from the FDA label →

  • Valsartan Being discontinued 4 products · updated November 19, 2025

    Cardiovascular

    Product Availability Expected supply / notes
    Valsartan, Tablet, 80 mg (NDC 0378-5813-77)
    Mylan Pharmaceuticals Inc., a Viatris Company
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 19, 2025
    Valsartan, Tablet, 160 mg (NDC 0378-5814-77)
    Mylan Pharmaceuticals Inc., a Viatris Company
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 19, 2025
    Valsartan, Tablet, 40 mg (NDC 0378-5807-93)
    Mylan Pharmaceuticals Inc., a Viatris Company
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 19, 2025
    Valsartan, Tablet, 320 mg (NDC 0378-5815-77)
    Mylan Pharmaceuticals Inc., a Viatris Company
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 19, 2025

    Uses, warnings and side effects from the FDA label →

  • Montelukast Sodium Being discontinued 1 product · updated November 17, 2025

    Pulmonary/Allergy

    Product Availability Expected supply / notes
    Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01)
    Organon
    Discontinuation of the manufacture of the drug
    Being discontinued · November 17, 2025

    Uses, warnings and side effects from the FDA label →

  • Ceftazidime Being discontinued 2 products · updated November 14, 2025

    Anti-Infective

    Product Availability Expected supply / notes
    Tazicef, Injection, 2 g (NDC 0409-5093-11)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · November 14, 2025
    Tazicef, Injection, 1 g (NDC 0409-5092-16)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · November 14, 2025

    Uses, warnings and side effects from the FDA label →

  • Palonosetron Hydrochloride Being discontinued 1 product · updated November 14, 2025

    Gastroenterology

    Product Availability Expected supply / notes
    Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01)
    Teva Pharmaceuticals USA, Inc.
    Discontinuation of the manufacture of the drug
    Being discontinued · November 14, 2025

    Uses, warnings and side effects from the FDA label →

  • Somatropin Being discontinued 1 product · updated November 14, 2025

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)
    Novo Nordisk, Inc.
    Discontinuation of the manufacture of the drug
    Being discontinued · November 14, 2025

    Uses, warnings and side effects from the FDA label →

  • Vancomycin Hydrochloride Being discontinued 1 product · updated November 14, 2025

    Anti-Infective

    Product Availability Expected supply / notes
    Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · November 14, 2025

    Uses, warnings and side effects from the FDA label →

  • Cetrorelix Acetate Being discontinued 1 product · updated November 13, 2025

    Reproductive

    Product Availability Expected supply / notes
    Cetrorelix Acetate, Injection, Kit (NDC 0480-5795-08)
    Teva Pharmaceuticals USA, Inc.
    Discontinuation of the manufacture of the drug
    Being discontinued · November 13, 2025

    Uses, warnings and side effects from the FDA label →

  • Guanfacine Being discontinued 4 products · updated November 13, 2025

    Psychiatry

    Product Availability Expected supply / notes
    Guanfacine Hydrochloride, Tablet, Extended Release, 2 mg (NDC 0228-2851-11)
    Actavis Pharma, Inc.
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 13, 2025
    Guanfacine Hydrochloride, Tablet, Extended Release, 4 mg (NDC 0228-2855-11)
    Actavis Pharma, Inc.
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 13, 2025
    Guanfacine Hydrochloride, Tablet, Extended Release, 3 mg (NDC 0228-2853-11)
    Actavis Pharma, Inc.
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 13, 2025
    Guanfacine Hydrochloride, Tablet, Extended Release, 1 mg (NDC 0228-2850-11)
    Actavis Pharma, Inc.
    A business decision was made to discontinue manufacture of the drug.
    Being discontinued · November 13, 2025

    Uses, warnings and side effects from the FDA label →

  • Atropine Sulfate Being discontinued 2 products · updated November 7, 2025

    Anesthesia, Neurology, Pediatric

    Product Availability Expected supply / notes
    Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)"
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025
    Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)"
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025

    Uses, warnings and side effects from the FDA label →

  • Calcium Chloride Being discontinued 1 product · updated November 7, 2025

    Cardiovascular, Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025

    Uses, warnings and side effects from the FDA label →

  • Deferiprone Being discontinued 1 product · updated November 7, 2025

    Hematology

    Product Availability Expected supply / notes
    Ferriprox, Tablet, 500 mg (NDC 10122-100-10)
    Chiesi USA, Inc.
    Discontinuation of the manufacture of the drug.
    Being discontinued · November 7, 2025

    Uses, warnings and side effects from the FDA label →

  • Dextrose Monohydrate Being discontinued 1 product · updated November 7, 2025

    Endocrinology/Metabolism, Gastroenterology, Pediatric

    Product Availability Expected supply / notes
    Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34)
    Hospira, Inc., a Pfizer Company
    Discontinuation of the manufacture of the drug
    Being discontinued · November 7, 2025

Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.

Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.

Advertisement